Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
Stopped Terminated for administrative reasons before enrollment was complete.
Conditions
- Atypical Hemolytic Uremic Syndrome
Interventions
Sponsor
Alexion Pharmaceuticals, Inc.